title: Antiangiogenic therapies for malignant pleural mesothelioma.
abstract: Malignant pleural mesothelioma (MPM), arises from the mesothelial cells, is difficult to be diagnosed at an early stage, and is refractory to conventional chemotherapy and radiotherapy. Therefore, the establishment of novel effective therapies is necessary to improve the prognosis for many patients with this disease. Recent studies have demonstrated that angiogenesis plays a significant role in MPM progression, suggesting the importance of tumor vessels as therapeutic targets. To explore molecular pathogenesis and evaluate the efficacy of vascular targeting therapy in MPM, we developed orthotopic implantation SCID mouse models of MPM. We found that selective VEGF inhibitors were effective only in the treatment of high-VEGF-producing MPM models. On the other hand, multiple kinase inhibitor E7080, with inhibitory activity against various angiogenic cytokine receptors, suppressed the progression and prolonged survival of both high-VEGF-producing and low-VEGF-producing MPM models. Further understanding of the functional characteristics of tumor angiogenesis may be essential to improve targeting therapies in MPM. In this review, we introduce current status of clinical strategies and novel therapeutic approaches against angiogenesis in MPM.
authors.affiliation: Division of Medical Oncology, Cancer Research Institute, Kanazawa University. Kanazawa, Ishikawa 920-0934, Japan. syano@staff.kanazawa-u.ac.jp
authors.forename: Seiji
authors.initials: S
authors.lastname: Yano
authors.forename: Qi
authors.initials: Q
authors.lastname: Li
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Tadaaki
authors.initials: T
authors.lastname: Yamada
authors.forename: Shinji
authors.initials: S
authors.lastname: Takeuchi
authors.forename: Emiko
authors.initials: E
authors.lastname: Nakataki
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Ogino
authors.forename: Hisatsugu
authors.initials: H
authors.lastname: Goto
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Nishioka
authors.forename: Saburo
authors.initials: S
authors.lastname: Sone
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D006801:Humans; D008654:Mesothelioma / Q000188:drug therapy* / Q000378:metabolism; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use; D016066:Pleural Effusion, Malignant / Q000188:drug therapy; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011799:Quinazolines / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use*; D035423:Thoracic Cavity; D042442:Vascular Endothelial Growth Factors / Q000096:biosynthesis / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D010880:Piperidines; D011799:Quinazolines; D011804:Quinolines; D042442:Vascular Endothelial Growth Factors; D000068258:Bevacizumab; C531958:lenvatinib; C452423:vandetanib